Rapport Therapeutics Inc. (NASDAQ: RAPP)’s stock price has dropped by -8.17 in relation to previous closing price of 20.31. Nevertheless, the company has seen a loss of -8.22% in its stock price over the last five trading days. globenewswire.com reported 2024-09-17 that Veuillez trouver ci-joint le rapport annuel Pilier 3 au 30 juin 2024 Attachment Rapport semestriel Pilier 3 – 30 juin 2024
Is It Worth Investing in Rapport Therapeutics Inc. (NASDAQ: RAPP) Right Now?
There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RAPP is 17.97M, and at present, short sellers hold a 7.75% of that float. The average trading volume of RAPP on October 03, 2024 was 162.06K shares.
RAPP’s Market Performance
The stock of Rapport Therapeutics Inc. (RAPP) has seen a -8.22% decrease in the past week, with a -7.86% drop in the past month, and a -19.96% fall in the past quarter. The volatility ratio for the week is 7.53%, and the volatility levels for the past 30 days are at 9.24% for RAPP. The simple moving average for the past 20 days is -7.58% for RAPP’s stock, with a -14.39% simple moving average for the past 200 days.
Analysts’ Opinion of RAPP
Stifel, on the other hand, stated in their research note that they expect to see RAPP reach a price target of $35. The rating they have provided for RAPP stocks is “Buy” according to the report published on July 02nd, 2024.
Jefferies gave a rating of “Buy” to RAPP, setting the target price at $35 in the report published on July 02nd of the current year.
RAPP Trading at -9.47% from the 50-Day Moving Average
After a stumble in the market that brought RAPP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.58% of loss for the given period.
Volatility was left at 9.24%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares sank -12.03% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.35% lower at present.
During the last 5 trading sessions, RAPP fell by -8.22%, in comparison to the 20-day moving average, which settled at $20.05. In addition, Rapport Therapeutics Inc. saw -10.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPP starting from HEALY JAMES, who purchase 44,032 shares at the price of $24.52 back on Jul 01 ’24. After this action, HEALY JAMES now owns 40,851 shares of Rapport Therapeutics Inc., valued at $1,079,575 using the latest closing price.
HEALY JAMES, the Director of Rapport Therapeutics Inc., purchase 558,824 shares at $17.00 during a trade that took place back on Jun 10 ’24, which means that HEALY JAMES is holding 1,863,327 shares at $9,500,008 based on the most recent closing price.
Stock Fundamentals for RAPP
The total capital return value is set at -0.11.
Based on Rapport Therapeutics Inc. (RAPP), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.66.
Currently, EBITDA for the company is -36.07 million with net debt to EBITDA at 2.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 42.08.
Conclusion
In summary, Rapport Therapeutics Inc. (RAPP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
